Good morning, you're tuned in to Markets Desk.
Tesla is raising Cybertruck prices by five thousand dollars across two trims, a move that signals the company is deliberately steering the angular pickup toward the luxury segment rather than chasing mass-market volume. With sales falling well short of Elon Musk's earlier targets, the price hike is less a growth strategy and more a margin defense.
Shifting to the broader market, one closely watched strategist is arguing the S&P five hundred has a clear path toward the seventy-nine hundred to eight thousand level, but only if it successfully clears three significant catalysts this week. Those events carry real weight, and the market's ability to navigate them cleanly will tell us a great deal about how durable this rally actually is.
Meanwhile, in pharma, Biohaven and SK Biopharmaceuticals have announced a global licensing and collaboration deal centered on Biohaven's Kv seven ion channel platform, with the lead asset targeting epilepsy. Biohaven shares moved higher on the news, reflecting investor confidence that the partnership adds meaningful commercial runway to what has been a closely watched pipeline program.
That's the tape. Markets Desk, signing off the floor.
